2006 Fiscal Year Final Research Report Summary
Proteomic analysis of Crow-Fukase syndrome
| Project/Area Number |
17590888
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
HASHIGUCHI Teruto Kagoshima University, Graduate School of Medical and Dental Sciences, Associate Professor (70250917)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MARUYAMA Ikuro Kagoshima University, Graduate School of Medical and Dental Sciences, Professor (20082282)
ABEYAMA Kazuhiro Kagoshima University, Graduate School of Medical and Dental Sciences, Visiting Associate Professor (30284897)
ARIMURA Kimiyishi Kagoshima University, Graduate School of Medical and Dental Sciences, Associate Professor (20159510)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Keywords | Crow-Fukase syndrome / POEMS syndrome / proteome / proteomics / peptidome / VEGF / brain / nerve |
|---|
| Research Abstract |
Objective : This study aimed to establish a diagnostic method for detecting what molecules have been degraded and what is going to progress next, by comprehensively and rapidly identifying peptide fragments in the patient's serum throughout subsequent pathological stages, thereby developing a diagnostic method that contributes to determining the appropriate direction of strategies for assessment of the pathological condition, nutritional support, and drug treatment. Methods : New proteome analysis technology, developed by Protosera Inc., was applied for the differential profiling of untreated serum samples from normal subjects and the same patient with Crow-Fukase Syndrome (POEMS Syndrome),an intractable inflammatory disorder, in the stable (at the time of diagnosis),exacerbation, DIC, and MOF stages, and MS/MS de novo sequencing of significantly different MS peaks was performed. A similar analysis was conducted of untreated serum samples from normal subjects and patients with six different types of early cancer. Results : We identified 94 low-molecular-weight peptide fragments that characteristically appeared in the DIC and MOF stages. These peptide fragments were derived from carrier proteins, such as transthyretin and protease inhibitors such as α1-antitrypsin. Moreover, some of these 94 peptide fragments coincided with the peptide fragment peaks that were characteristically observed in the respective early cancer patients. Discussion : The patterns of low-molecular-weight peptide fragments that appear in the blood reflect the activation of proteases characterizing the biological environment, including that of normal subjects and patients with cancer, DIC, or MOF, thereby providing valuable information on pathological conditions. We consider that these results will lead to the development of a method that contributes to determining the appropriate direction of strategies for pathological condition diagnosis, nutritional support, and drug treatment.
|
